TID 1000 mg Mesalazine Versus TID 2x500 mg Mesalazine in Active Ulcerative Colitis (UC)

Active Ulcerative Colitis Clinical Trial

Official title:
Double-blind, Double-dummy, Randomised, Multi-centre, Comparative Phase III Clinical Study on the Efficacy and Tolerability of an 8 Week Oral Treatment With Three Times Daily 1000 mg Mesalazine Versus Three Times Daily 2x500 mg Mesalazine in Patients With Active Ulcerative Colitis

Status Completed

Clinical Trial Summary

The purpose of the trial is to proof whether TID 1000 mg mesalazine is non-inferior to TID 2x 500 mg mesalazine in the treatment of patients with acute ulcerative colitis

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01745770
Study type	Interventional
Source	Dr. Falk Pharma GmbH
Contact
Status	Completed
Phase	Phase 3
Start date	January 2013
Completion date	June 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00603733` - Canadian Active & Maintenance Modified Pentasa Study	Phase 3
Completed	`NCT01257386` - Comparative Efficacy and Safety Study in Patients With Active Ulcerative Colitis	Phase 3
Completed	`NCT00616434` - A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis	Phase 2
Completed	`NCT02748590` - Evaluation of Sacral Neuromodulation (SNM) in the Treatment of Active Ulcerative Colitis (PRIMICISTIM)	N/A
Completed	`NCT03235752` - Safety and Efficacy of TJ301 IV in Participants With Active Ulcerative Colitis	Phase 2
Recruiting	`NCT05739864` - Superdonor FMT in Patients With Ulcerative Colitis	Phase 1/Phase 2